Researchers develop decision-making tool to benefit patients with HCV

June 18, 2018, Beth Israel Deaconess Medical Center

An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention. It is the most common cause for cirrhosis and liver cancer in the United States and the leading indication for liver transplantation. While recently developed direct anti-viral agents (DAAs) have proven to be a highly effective treatment option for many patients with HCV, those with decompensated HCV cirrhosis or liver failure may experience little to no improvement in liver function following eradication of HCV.

Published in the June, 2018, issue of Gastroenterology, BIDMC researchers led a retrospective analysis of four randomized clinical trials focused on the effects of DAA therapies in patients with HCV-associated , and developed a new means of predicting improvement in in response to DAA treatment. The online scoring system, called the BE3A score, assesses 5 baseline factors (body mass index, encephalopathy, ascites and serum levels of alanine aminotransferase and albumin) to provide physicians with a shared decision-making tool to quantify the potential benefits of DAA therapy for patients with decompensated cirrhosis.

"Doctors and patients need to decide when a patient should receive HCV treatment in the setting of decompensated cirrhosis from HCV and whether to treat before, or defer treatment until after liver transplant," wrote study authors Michael P. Curry, MD, Section Chief of Hepatology at BIDMC and Z. Gordon Jiang, MD, a translational investigator at BIDMC's Liver Center. "Our study combined all of the data from smaller studies, allowing us to have a large enough sample size to determine predictors of improvement in liver function. With this analysis, we created a tool for shared decision-making for doctors and patients in this exact clinical scenario. "

Explore further: Treating patients for hepatitis C could reduce the need for liver transplants

Related Stories

Treating patients for hepatitis C could reduce the need for liver transplants

April 14, 2016
A new study presented today demonstrates that patients on the liver transplant list with Hepatitis C virus (HCV) and severe liver damage were more likely to be taken off the list or have their need of a liver transplant reduced ...

Combination therapy successfully treats hepatitis C in patients with advanced liver disease

November 30, 2015
A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the ...

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Treatment of HCV allows for sustained removal from the liver transplant waiting list

April 21, 2017
A new European study presented today demonstrated that patients with chronic Hepatitis C virus (HCV) and severe liver damage, taken off the liver transplant list as a result of successful direct-acting antiviral (DAA) therapy, ...

Combination therapy offers new hope for difficult-to-treat patients with chronic hepatitis C

April 23, 2015
Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high ...

Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in Italian cohort

April 13, 2018
Patients with chronic hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) after direct-acting antiviral agent (DAA) treatment have lower all-cause mortality, according to a real-world study ...

Recommended for you

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

Maternally acquired Zika immunity can increase dengue disease severity in mouse pups

November 14, 2018
To say that the immune system is complex is an understatement: an immune response protective in one context can turn deadly over time, as evidenced by numerous epidemiological studies on dengue infection, spanning multiple ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.